Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Simona Sacco, Antonio Russo, Pierangelo Geppetti, Licia Grazzi, Andrea Negro, Cristina Tassorelli, Gioacchino Tedeschi & Paolo Martelletti. (2020) What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. Expert Review of Neurotherapeutics 20:12, pages 1275-1286.
Read now
Read now
Cristina Tassorelli, Gioacchino Tedeschi, P Sarchielli, Luigi Alberto Pini, Licia Grazzi, Pierangelo Geppetti, Marina De Tommaso, Marco Aguggia, P Cortelli & Paolo Martelletti. (2018) Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert Review of Neurotherapeutics 18:2, pages 167-176.
Read now
Read now
Piero Barbanti & Patrizia Ferroni. (2017) Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations. Journal of Pain Research 10, pages 2319-2329.
Read now
Read now
Hongwei Zhang, Haifeng Zhang, Yingjie Wei, Yajun Lian, Yuan Chen & Yake Zheng. (2017) Treatment of chronic daily headache with comorbid anxiety and depression using botulinum toxin A: a prospective pilot study. International Journal of Neuroscience 127:4, pages 285-290.
Read now
Read now
Articles from other publishers (45)
Délia Szok, Anett Csáti, László Vécsei & János Tajti. (2023) Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review. Life 13:3, pages 665.
Crossref
Crossref
Cristina González-Mingot, Anna Gil-Sánchez, Marc Canudes-Solans, Silvia Peralta-Moncusi, Maria José Solana-Moga & Luis Brieva-Ruiz. (2022) Preventive treatment can reverse cognitive impairment in chronic migraine. The Journal of Headache and Pain 23:1.
Crossref
Crossref
Nailah Asif, Apurva Patel, Deepanjali Vedantam, Devyani S Poman & Lakshya Motwani. (2022) Migraine With Comorbid Depression: Pathogenesis, Clinical Implications, and Treatment. Cureus.
Crossref
Crossref
Negar Shaterian, Negin Shaterian, Aref Ghanaatpisheh, Farnaz Abbasi, Sara Daniali, Maryam Jalali Jahromi, Mohammad Sadegh Sanie & Amir Abdoli. (2022) Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review. Pain Research and Management 2022, pages 1-15.
Crossref
Crossref
Christopher Gottschalk, Anirban Basu, Andrew Blumenfeld, Bradley Torphy, Michael J Marmura, Jelena M Pavlovic, Paula K Dumas, Nim Lalvani & Dawn C Buse. (2022) The importance of an early onset of migraine preventive disease control: A roundtable discussion. Cephalalgia Reports 5, pages 251581632211345.
Crossref
Crossref
Oreste Affatato, Thiago C. Moulin, Claudia Pisanu, Victoria S. Babasieva, Marco Russo, Elif I. Aydinlar, Paola Torelli, Vladimir N. Chubarev, Vadim V. Tarasov, Helgi B. Schiöth & Jessica Mwinyi. (2021) High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis. Journal of Translational Medicine 19:1.
Crossref
Crossref
Alicia Gonzalez-Martinez, Álvaro Planchuelo-Gómez, Ángel L Guerrero, David García-Azorín, Sonia Santos-Lasaosa, María Pilar Navarro-Pérez, Paula Odriozola-González, María Jesús Irurtia, Sonia Quintas, Rodrigo de Luis-García & Ana Beatriz Gago-Veiga. (2021) Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown. Neurological Sciences 42:12, pages 5087-5092.
Crossref
Crossref
Ricardo Ortiz, Lisa Gfrerer, Marek A. Hansdorfer, Mia R. Colona, Jane M. Tsui & William G. Austen. (2021) The Relationship of Psychiatric Comorbidities and Their Impact on Trigger Site Deactivation Surgery for Headaches. Plastic & Reconstructive Surgery 148:5, pages 1113-1119.
Crossref
Crossref
Veronica Antipova, Carsten Holzmann, Alexander Hawlitschka, Martin Witt & Andreas Wree. (2021) Antidepressant-Like Properties of Intrastriatal Botulinum Neurotoxin-A Injection in a Unilateral 6-OHDA Rat Model of Parkinson’s Disease. Toxins 13:7, pages 505.
Crossref
Crossref
Richard B. Lipton, Joshua M. Cohen, Maja Galic, Michael J. Seminerio, Paul P. Yeung, Ernesto Aycardi, Marcelo E. Bigal, Kristen Bibeau & Dawn C. Buse. (2021) Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. Headache: The Journal of Head and Face Pain 61:4, pages 662-672.
Crossref
Crossref
Jasem Youssef Al-Hashel, Hasan Kh Ashkanani, Ohood Almutairi, Fajer A. Bokubar, Shahad Mubarak, Sawsan Alwazzan, Raed Alroughani, Doaa Youssry & Samar Farouk Ahmed. (2021) Onabotulinumtoxin A Improves Psychological Aspects in Chronic Migraine Patients. Frontiers in Neurology 11.
Crossref
Crossref
Yousif Mahdi, Abeer Eissa, Eman Shorub, Mona M. ElSheikh, Rabab Hamdy & Ahmed A. Moustafa. 2021. The Nature of Depression. The Nature of Depression
99
110
.
Hans O. Kalkman. (2020) Stress-Induced Alteration in Chloride Transporters in the Trigeminal Nerve May Explain the Comorbidity between Depression and Migraine. Psychiatry International 1:2, pages 36-41.
Crossref
Crossref
Florindo d'Onofrio, Arturo de Falco, Antonio Costanzo, Daniele Spitaleri, Gerardo Casucci & Simona Raimo. (2020) Impulse control disorders in chronic migraine with medication overuse after onabotulinumtoxinA: A single-center prospective cohort study. Journal of Clinical Neuroscience 80, pages 152-155.
Crossref
Crossref
Valeria Donisi, Maria Angela Mazzi, Marialuisa Gandolfi, Giuseppe Deledda, Fabio Marchioretto, Simone Battista, Sara Poli, Matteo Giansante, Eleonora Geccherle, Cinzia Perlini, Nicola Smania & Lidia Del Piccolo. (2020) Exploring Emotional Distress, Psychological Traits and Attitudes in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylaxis versus Withdrawal Treatment. Toxins 12:9, pages 577.
Crossref
Crossref
Richard B. Lipton, Joshua M. Cohen, Sanjay K. Gandhi, Ronghua Yang, Paul P. Yeung & Dawn C. Buse. (2020) Effect of fremanezumab on quality of life and productivity in patients with chronic migraine. Neurology 95:7, pages e878-e888.
Crossref
Crossref
Alicia Alpuente, Víctor José Gallardo, Marta Torres‐Ferrús, José Álvarez‐Sabin & Patricia Pozo‐Rosich. (2020) Short and Mid‐Term Predictors of Response to OnabotulinumtoxinA: Real‐Life Experience Observational Study. Headache: The Journal of Head and Face Pain 60:4, pages 677-685.
Crossref
Crossref
Susan Ho, David Darby & Natasha Bear. (2020) Cognitive effects of onabotulinumtoxinA in chronic migraine. BMJ Neurology Open 2:1, pages e000014.
Crossref
Crossref
Minhong Tang, Jianghui Meng & Jiafu Wang. (2019) New Engineered-Botulinum Toxins Inhibit the Release of Pain-Related Mediators. International Journal of Molecular Sciences 21:1, pages 262.
Crossref
Crossref
Thomas Dresler, Salvatore Caratozzolo, Kaat Guldolf, Jana-Isabel Huhn, Carmela Loiacono, Triinu Niiberg-Pikksööt, Marta Puma, Giorgia Sforza, Anna Tobia, Raffaele Ornello & Gianluca Serafini. (2019) Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. The Journal of Headache and Pain 20:1.
Crossref
Crossref
Minna A. Korolainen, Samu Kurki, Mariann I. Lassenius, Iiro Toppila, Madlaina Costa-Scharplatz, Timo Purmonen & Markku Nissilä. (2019) Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care. The Journal of Headache and Pain 20:1.
Crossref
Crossref
Gandolfi, Donisi, Marchioretto, Battista, Smania & Del Piccolo. (2019) A Prospective Observational Cohort Study on Pharmacological Habitus, Headache-Related Disability and Psychological Profile in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylactic Treatment. Toxins 11:9, pages 504.
Crossref
Crossref
Francesca Schiano di Cola, Salvatore Caratozzolo, Paolo Liberini, Renata Rao & Alessandro Padovani. (2019) Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A Treatment. Frontiers in Neurology 10.
Crossref
Crossref
Licia Grazzi, Eleonora Grignani, Emanuela Sansone, Alberto Raggi, Domenico D’Amico & Frank Andrasik. (2019) Catastrophizing attitude changes after onabotulinumtoxin A treatment in chronic migraine. Neurological Sciences 40:S1, pages 201-202.
Crossref
Crossref
Andrew M Blumenfeld, Stewart J Tepper, Lawrence D Robbins, Aubrey Manack Adams, Dawn C Buse, Amelia Orejudos & Stephen D Silberstein. (2019) Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. Journal of Neurology, Neurosurgery & Psychiatry 90:3, pages 353-360.
Crossref
Crossref
Dawn C. Buse, Jacob D. Greisman, Khosrow Baigi & Richard B. Lipton. (2018) Migraine Progression: A Systematic Review. Headache: The Journal of Head and Face Pain 59:3, pages 306-338.
Crossref
Crossref
Eva Bruloy, Raphael Sinna, Jean-Louis Grolleau, Apolline Bout-Roumazeilles, Emilie Berard & Benoit Chaput. (2019) Botulinum Toxin versus Placebo. Plastic and Reconstructive Surgery 143:1, pages 239-250.
Crossref
Crossref
Teshamae S. Monteith. 2019. Chronic Headache. Chronic Headache
37
62
.
Miguel J. A. Láinez & Ane Mínguez-Olaondo. 2019. Chronic Headache. Chronic Headache
217
230
.
M. Axel Wollmer, Michelle Magid, Tillmann H. C. Kruger & Eric Finzi. 2021. Botulinum Toxin Therapy. Botulinum Toxin Therapy
265
278
.
Lars Bendtsen, Simona Sacco, Messoud Ashina, Dimos Mitsikostas, Fayyaz Ahmed, Patricia Pozo-Rosich & Paolo Martelletti. (2018) Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. The Journal of Headache and Pain 19:1.
Crossref
Crossref
Cristina Tassorelli, Grazia Sances, Micol Avenali, Roberto De Icco, Daniele Martinelli, Vito Bitetto, Giuseppe Nappi & Giorgio Sandrini. (2018) Botulinum toxin for chronic migraine: Clinical trials and technical aspects. Toxicon 147, pages 111-115.
Crossref
Crossref
Licia Grazzi, Eleonora Grignani, Emanuela Sansone, Alberto Raggi, Matilde Leonardi & Domenico D’Amico. (2018) Onabotulinumtoxin A for chronic migraine with medication overuse: clinical results and changes in catastrophising attitude. Preliminary data. Neurological Sciences 39:S1, pages 173-174.
Crossref
Crossref
Licia Grazzi, Emanuela Sansone, Alberto Raggi, Domenico D’Amico, Andrea De Giorgio, Matilde Leonardi, Laura De Torres, Francisco Salgado-García & Frank Andrasik. (2017) Mindfulness and pharmacological prophylaxis after withdrawal from medication overuse in patients with Chronic Migraine: an effectiveness trial with a one-year follow-up. The Journal of Headache and Pain 18:1.
Crossref
Crossref
Elif Ilgaz Aydinlar, Pinar Yalinay Dikmen, Seda Kosak & Ayse Sagduyu Kocaman. (2017) OnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study. The Journal of Headache and Pain 18:1.
Crossref
Crossref
Simona Guerzoni, Lanfranco Pellesi, Carlo Baraldi & Luigi Alberto Pini. (2016) Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment. The Journal of Headache and Pain 17:1.
Crossref
Crossref
Stephanie M. Llop, Jonathan E. Frandsen, Kathleen B. Digre, Bradley J. Katz, Alison V. Crum, Chong Zhang & Judith E. A. Warner. (2016) Increased prevalence of depression and anxiety in patients with migraine and interictal photophobia. The Journal of Headache and Pain 17:1.
Crossref
Crossref
Bekir Enes Demiryurek, Devrimsel Harika Ertem, Atilla Tekin, Mustafa Ceylan, Yesim Guzey Aras & Belma Dogan Gungen. (2016) Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine. Neurological Sciences 37:11, pages 1779-1784.
Crossref
Crossref
Arne May & Laura H. Schulte. (2016) Chronic migraine: risk factors, mechanisms and treatment. Nature Reviews Neurology 12:8, pages 455-464.
Crossref
Crossref
Mia Tova Minen, Olivia Begasse De Dhaem, Ashley Kroon Van Diest, Scott Powers, Todd J Schwedt, Richard Lipton & David Silbersweig. (2016) Migraine and its psychiatric comorbidities. Journal of Neurology, Neurosurgery & Psychiatry 87:7, pages 741-749.
Crossref
Crossref
Marco Russo, Gian Camillo Manzoni, Arens Taga, Antonio Genovese, Licia Veronesi, Cesira Pasquarella, Giuliano Ezio Sansebastiano & Paola Torelli. (2016) The use of onabotulinum toxin A (Botox®) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study. Neurological Sciences 37:7, pages 1127-1131.
Crossref
Crossref
Tillmann H.C. Kruger & M. Axel Wollmer. (2015) Depression – An emerging indication for botulinum toxin treatment. Toxicon 107, pages 154-157.
Crossref
Crossref
Kasra Maasumi, Nicolas R. Thompson, Jennifer S. Kriegler & Stewart J. Tepper. (2015) Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine. Headache: The Journal of Head and Face Pain 55:9, pages 1218-1224.
Crossref
Crossref
Silja Tölzel & Göran Hajak. (2015) Botulinumtoxin — ein Neuromodulator zur effektiven Therapie von Depression?. DNP - Der Neurologe und Psychiater 16:7-8, pages 24-32.
Crossref
Crossref
Délia Szok, Anett Csáti, László Vécsei & János Tajti. (2015) Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety. Toxins 7:7, pages 2659-2673.
Crossref
Crossref